Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation. Backed by Bessemer.
About the role
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.
What they're looking for
- Advanced degree in a scientific or engineering discipline strongly preferred (e.g., PhD or MS in biology, immunology, pharmacology, biomedical engineering, bioengineering, chemical engineering, or a related field)
- Demonstrated ability to rapidly understand complex biology, mechanisms of action, clinical trial design, endpoints, and therapeutic landscapes and connect them to strategic and commercial implications
- Fluency in primary and secondary market research and comfort managing external vendors and expert interviews
- Experience building or critically evaluating patient-based forecasts, epidemiology models, scenario analyses, and commercial opportunity assessments
- Excellent written and verbal communication skills, including the ability to create concise, executive-ready PowerPoint materials and communicate effectively with scientific and senior business audiences
- High level of proficiency with Excel and PowerPoint, strong comfort adopting AI-enabled research, synthesis, and knowledge-management tools and using them responsibly
More about this role
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn .
- PIONEER : We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
- COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
- BELONG : We recognize our differences, inviting...
Browse similar: Startup jobs